ArticleInternational journal of nanomedicine2025
Biomimetic Nanoplatform Based on the Neutrophil Membrane for Targeted Therapy of Spinal Cord Injury.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Carrier-Free Rapamycin-Loaded Nanoparticles with MRI and Near-Infrared Fluorescence Bimodal Imaging for Precise Diagnosis and Synergistic Therapy of Ischemic Stroke.International journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Spinal cord injury (SCI) triggers a cascade of secondary damage, including oxidative stress and neuroinflammation, for which effective treatments remain limited. To address this, we developed a biomimetic nanoplatform, NEU@MPBNPs-HED, consisting of mesoporous Prussian blue nanoparticles (MPBNPs) loaded with hederagenin (HED) and cloaked with neutrophil membranes (NEUm) to enhance lesion targeting and immune evasion. Methods: The physicochemical properties, drug release characteristics, and cellular uptake of NEU@MPBNPs-HED were characterized. Therapeutic efficacy was evaluated in vitro using oxygen-glucose deprivation/reoxygenation (OGD/R) models of neuronal injury and in vivo in a murine spinal cord contusion model. Key outcomes included neuronal survival, oxidative stress, apoptosis, motor recovery, and biodistribution. Results: In vitro, NEU@MPBNPs-HED significantly improved HT22 neuronal viability by 48.6%, reduced intracellular reactive oxygen species (ROS) by 52.4%, and preserved mitochondrial membrane potential compared with free HED or non-biomimetic controls. Apoptosis was suppressed through modulation of Bax, Bcl-2, and cytochrome C. In vivo, NEU@MPBNPs-HED enhanced Basso Mouse Scale (BMS) scores, improved motor evoked potentials, promoted axonal regeneration (NF200↑), and reduced glial scarring (GFAP↓). Moreover, the oxidative stress marker (MDA), inflammatory indicators (TNF-α, and Ly6G+ cells, and Arg1) were reduced. Biodistribution studies confirmed selective accumulation at the injury site, and histological analyses revealed no systemic toxicity. Conclusion: The NEU@MPBNPs-HED nanoplatform effectively targeted spinal cord lesions, attenuated oxidative and inflammatory damage, and promoted neurological recovery. These findings highlight the translational potential of biomimetic nanotherapies for treating traumatic central nervous system disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.